CSPC Pharmaceutical Group logo

CSPC Pharmaceutical Group

Asia, Hebei, China, Shijiazhuang

Description

CSPC Pharmaceutical Group is a pharmaceutical group in China.

Investor Profile

CSPC Pharmaceutical Group has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B rounds (top funding stages).
  • Majority of deals are located in China.
  • Strong thematic focus on Biopharma, Biotechnology, Health Care.

Stage Focus

  • Series B (100%)

Country Focus

  • China (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does CSPC Pharmaceutical Group frequently co-invest with?

Daehwa Pharmaceutical
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Hillhouse Investment
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
3H Health Investment
Asia, Hong Kong Island, Hong Kong, Cyberport
Co-Investments: 1
ALAN AMC
Asia, Beijing, China, Beijing
Co-Investments: 1
Huagai Capital
Asia, Beijing, China, Beijing
Co-Investments: 1
CASVC
Asia, Beijing, China, Beijing
Co-Investments: 1
Atlas Capital LLC
North America, Arizona, United States, Phoenix
Co-Investments: 1
BioTrack Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Elite Capital
Asia, Beijing, China, Beijing
Co-Investments: 1
Yingke Capital
Asia, Jiangxi, China, Fuzhou
Co-Investments: 2

What are some of recent deals done by CSPC Pharmaceutical Group?

Haihe Biopharma

Shanghai, Shanghai, China

Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical
Series BJul 24, 2020
Amount Raised: $171,005,942
Haihe Biopharma

Shanghai, Shanghai, China

Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical
Series BFeb 11, 2019
Amount Raised: $146,600,000